New targeting strategy for lupus erythematosus

Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.

The treatment is based on a novel targeting strategy for stopping autoimmunity in patients.

The innovation

The treatment is better way to treat systemic lupus erythematosus that shows markedly reduced autoimmunity without compromising B-cell survival.

Market need

Systemic lupus erythematosus is a debilitating and chronic autoimmune disease affecting more than five million people worldwide. Efficacy rates of current treatments are modest, and some deplete beneficial B-cells, greatly weakening the immune system and increasing risk of infections. On top of this, state-of-the-art treatments are costly.

Innovation status

Studies have identified a unique targeting approach based on selectively removing a highly inflammatory component of B-cell activating factor that is differential to the BAFF targeting approaches that are currently in the market or in development.

A biomarker to stratify patients for disease severity and the pathogenic mechanism has also been identified, enabling relevant subgroup targeting in clinical trials.



Download flyer for more information (PDF)